Benz Sciences Inc. announced today that it entered into a license agreement with Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) for TAS1440, a clinical stage LSD1 (lysine-specific demethylase 1) inhibitor discovered by Taiho Pharmaceutical.

Benz Sciences is a special purposed company, which was established by SFG SCIENCES Inc. with the aim to develop TAS1440 (new development code: SFG-03). Under the terms of agreement, Benz Sciences will obtain exclusive worldwide rights to develop, manufacture and commercialize TAS1440, and will undertake preparations in the United States for the Phase 1b/2 trial of TAS1440 for the treatment of myeloproliferative neoplasms.

For more details, please click the link of the News Release.
https://www.taiho.co.jp/en/release/2025/20250602.html